Total: $1,211.07M | ||||
Company |
Type Of |
Number |
Amount |
Investors; Placement Agents; |
Acusphere |
Registered |
9.259S and 3.7W |
$25.5 |
Units consisting of one share and 0.4 warrants were sold at $2.75 each; the four-year warrants are exercisable at $3.11 per share; Cowen and Co. LLC was placement agent (12/7) |
Advancis |
Private placement of stock |
6S |
$18 |
Shares were sold at $3 each to new and existing investors; Pacific Growth Equities LLC was lead placement agent; Susquehanna Financial Group LLP was co-agent (12/11) |
Akesis |
Private placement of stock and warrants |
1.383S and 0.207W |
$0.8 |
The shares were sold at $0.60 each; the three-year warrants are exercisable at the same price; Akesis also established a $1M credit facility with Square 1 Bank (12/18) |
Alexza |
Product- specific vehicle |
N/A |
$50 |
Symphony Capital Partners LP and co- investors bought an interest in Alexza products AZ-002 and AZ-004, both in Phase IIa trials in central nervous system indications; Alexza has an option to reacquire all rights (12/4) |
Alizyme plc |
Private placement of stock |
18.12S |
£14.5 ($28.3) |
Shares were placed with UK institutional investors at 80 pence each; Piper Jaffray Ltd. was placement agent (12/1) |
Antisoma |
Private placement of stock |
73.97S |
£26.3 ($51.3) |
The stock was sold to existing and new investors at 35.5 pence per share; Piper Jaffray Ltd. managed the deal; Needham & Co. LLC was co- manager (12/15) |
Biomira Inc. |
Private placement of stock and warrants |
9.63S and 1.926W |
$13 |
Biomira sold units consisting of one share and 0.20 warrants at $1.35 each; the four-year warrants are exercisable at $1.86 per share; Rodman & Renshaw LLC was placement agent (12/13) |
Callisto |
Private placement of convertible stock and warrants |
0.402S and 5.361W |
$4.02 |
The company sold 402,100 Series A convertible shares, and 1.4M five-year warrants exercisable at $0.75 per share; it was the second tranche of a deal that totaled about $5.75M (12/27) |
CeNeS |
Private placement of stock |
74.12S |
£4.82 ($9.4) |
The shares were placed at 6.5 pence each; JM Finn & Co. Ltd. was placement agent (12/4) |
Ceragenix |
Private placement of notes and warrants |
N/A and 1.16W |
$5 |
The three-year, 9% notes initially are convertible into stock at $2.26 per share; the five-year warrants are exercisable at $2.37 per share; Stifel, Nicolaus & Co. Inc. was lead placement agent (12/11) |
Cerus Corp. |
Private placement of stock |
3.904S |
$26.1 |
The registered shares are being sold at $6.68 each; Banc of America Securities LLC was lead placement agent; Robert W. Baird & Co. Inc. was co-agent (12/6) |
China |
Sale of convertible debt and warrants |
N/A and 12W |
$3 |
The $3M in 9% notes is convertible into common stock at $0.25 per share; warrants are exercisable at $0.30 and $0.40 per share; Melton Management Ltd. was agent for the deal (12/14) |
Clinical Cell |
Placement and share purchase plan |
202.5S |
A$13.77 ($11) |
A$10M of the deal came from a share purchase plan underwritten by Potter Securities Ltd.; A$3.77M came from a sale to Hunter Hall Investment Management Ltd. and others; shares were sold at 6.8 cents each in both deals (12/7) |
Cobalis Corp. |
Private placement of convertible notes and |
N/A and 6.6W |
$3.85 |
The 8% notes are convertible into stock at the lower of $0.99 or 90% of the lowest three-day average over 15 trading days; the warrants are exercisable at prices ranging from about $0.75 to $1 per share (12/21) |
Columbia |
Private placement of notes and warrants |
N/A and ND |
$40 |
The company sold convertible subordinated notes and warrants to existing institutional investors; terms of the deal were not disclosed (12/26) |
CombiMatrix |
Registered direct offering |
9.8S and |
$10 |
9.8M units were sold at $1.02 apiece; each consists of one share and 1.2 warrants exercisable at $0.87 per share; Oppenheimer & Co. Inc. was placement agent (12/8) |
Conjuchem |
Sale of stock and warrants |
185S and |
C$120.25($103) |
Units in an offering were sold at C$0.65 apiece; each consists of one share and half a warrant; each whole warrant is exercisable for three years at C$1 per share; Dundee Securities Corp. and Sprott Securities Inc. were lead underwriters; others were Orion Securities Inc. and Versant Partners Inc. (11/28)& |
Cytokinetics |
Registered direct offering |
5.286S |
$37 |
The registered shares were sold at $7 each, a 6% discount to the Dec. 6 closing price; Lazard Capital Markets LLC was lead placement agent; JMP Securities LLC and Rodman & Renshaw LLC were co-agents (12/7) |
Depomed |
Equity |
N/A |
N/A |
Azimuth Opportunity Ltd. committed to purchase up to $30M in registered Depomed stock over two years, at a discount; any sales would be at Depomed's sole discretion (12/12) |
EntreMed |
Registered direct offering |
10.728S |
$17.2 |
Institutional investors purchased the registered shares at $1.60 each; ThinkEquity Partners LLC was lead placement agent; Rodman & Renshaw LLC was co-agent(12/13) |
Enzo |
Registered direct offering |
3.286S |
$46 |
The registered stock was sold at $14 per share; Lazard Capital Markets LLC was placement agent (12/15) |
EpiCept Corp. |
Private placement of stock and warrants |
6.8S and 3.4W |
$10 |
The stock was sold at $1.46 per share; the five-year warrants are exercisable, after six months, at $1.47 per share; Rodman & Renshaw LLC was placement agent (12/22) |
EpiCept Corp. |
Equity |
N/A |
N/A |
Cornell Capital Partners LP committed to purchase up to $15M in EpiCept stock at a discount over three years; EpiCept will determine the timing and amount of any sales(12/22) |
Favrille Inc. |
Equity financing commitment |
N/A |
N/A |
Kingsbridge Capital Ltd. committed to purchase up to $40M of Favrille stock over three years, at times and in amounts to be determined by Favrille (12/20) |
Galapagos |
Private placement of stock |
3.464S |
€31 ($40.7) |
Shares were sold to institutional investors in the U.S. and Europe at €8.95 each; Kempen & Co., Fortis and Whitaker Securities managed the deal (12/22) |
GenVec Inc. |
Registered direct offering |
9.61S |
$19.7 |
The registered stock was sold at $2.05 per share; Rodman & Renshaw LLC was placement agent (12/20) |
Geron Corp. |
Private placement of stock and warrants |
5S and 4.875W |
$40 |
The stock was sold at $8 per share; 1.875M warrants are exercisable at that price for 75 days; 3M warrants are exercisable after 180 days at an undisclosed premium; the company arranged the financing directly with investors (12/14) |
GTx Inc. |
Registered direct offering |
3.8S |
$60.8 |
The registered stock was sold at $16 per share, a 4.7% discount to the Dec. 12 price; Lazard Capital Markets LLC was lead placement agent; Cowen and Co. LLC was co-agent (12/13) |
ImmuneRegen |
Private placement of stock and warrants |
ND |
$5.5 |
The five-year warrants issued in the deal are exercisable at $0.50 per share; details on the financing were not disclosed (12/7) |
Immunicon |
Private placement of convertible notes |
N/A |
$30 |
The 6% notes are convertible into stock at $4.09 per share, or 7.33M shares; 1.47M warrants issued in the deal are exercisable at $4.09 per share; Deutsche Bank Securities Inc. was placement agent (12/5) |
ImmuPharma |
Private placement of stock and notes |
4.35S |
£4.71 ($9.2) | In one deal, 4.35M shares were sold at 62 pence each to funds managed by Jupiter, Martin Currie and Powe Capital; in another, ING Belgium provided €3M to ImmuPharma France SA in an interest-free bond, convertible for three years into 3.245M shares (12/21) |
Introgen |
Private placement of stock |
4.99S |
$24 |
The registered shares were sold at $4.80 each; Mulier Capital Ltd. was placement agent (12/14) |
Lipid |
Private placement of stock |
4.593S |
$6.2 |
Institutional investors led by RA Capital Management purchased the stock at $1.35 per share; Oppenheimer & Co. was placement agent (12/20) |
MannKind |
Offering of convertible notes |
N/A |
$115 |
The 3.75% notes due in 2013 were sold in a public offering; the intial conversion price is $22.47 per share; underwriters led by J.P Morgan Securities Inc. and Merrill Lynch & Co., along with Wachovia Capital Markets LLC, CIBC World Markets Corp. and Leerink Swann & Co. Inc., exercised their option to purchase $15M in notes (12/7) |
Medicure |
Private placement of stock and warrants |
19.9S and 3.98W |
$25.9 |
Institutional investors purchased the shares at $1.30 each; the five-year warrants are exercisable at $1.70 per share; Deutsche Bank Securities Inc. was lead placement agent; A.G. Edwards & Sons Inc. and Montgomery & Co. LLC were co-agents (12/20) |
Medivation |
Registered direct offering |
2.2S |
$35.75 |
The registered stock was sold at $16.25 per share; Cowen and Co. LLC was lead placement agent; co-placement agents were Leerink Swann & Co., Rodman & Renshaw LLC and Emerging Growth Equities Ltd. (12/8) |
Migenix Inc. |
Bought-deal financing |
2.51U |
C$1.5 |
A Canadian investment dealer exercised its overallotment option on 2.51M additional units from a C$10M financing in November; totals in the C$11.5M deal were 19.263M shares and 9.631M warrants (12/6) |
Neurogen |
Registered direct offering |
6.993S |
$40 |
The registered shares were sold at $5.72 each, the Dec. 18 closing price; Pacific Growth Equities LLC was lead placement agent; co-agents were CIBC World Markets Corp., Leerink Swann & Co. and Merriman Curhan Ford & Co. (12/19) |
Neuropharma |
Private placement of stock |
2.773S |
€31.53 ($41.7) |
Zeltia's stake in Neuropharma was reduced to 59% from 75.2% following the financing; the financing was managed by Banif (12/29) |
NexMed Inc. |
Private placement of stock and warrants |
13.317S and 5.327W |
$8.65 |
Southpoint Capital Advisors and RA Capital Management purchased the stock at $0.6501 per share; the five-year warrants are exercisable at $0.79 per share (12/21) |
NovaDel |
Private |
9.823S and |
$14.2 |
The stock was sold at $1.45 per share; the five-year warrants are exercisable at $1.70 per share; Oppenheimer & Co. was lead placement agent; Griffin Securities Inc. was co-agent (12/15) |
Ondine |
Bought-deal |
0.462S |
C$0.74 ($0.64) |
Underwriters of a C$10M financing in October exercised their option to purchase 0.462M additional shares; the deal totaled about 6.71M shares and C$10.74M in gross proceeds (12/7) |
ProMetic |
Private placement of stock |
65.138S |
C$17.14 ($14.7) |
In one deal, about 36.566M shares were sold at C$0.25 each; in a separate deal with Paradigm Capital Inc., about 28.57M shares were sold at C$0.28 each (12/28) |
Protherics plc |
Private placement of stock and open offer |
58.72S |
£38.2 ($75) |
Share were sold at 62 pence each; Nomura Code Securities Ltd. and Piper Jaffray Ltd. underwrote the deal (12/8) |
Protox |
Private placement of stock and warrants |
1.75S and 0.875W |
C$0.88 ($0.76) |
The deal completes a C$10M financing round, the first part of which closed in November; units consisting of one share and half a warrant were sold at C$0.50 each; each one-year warrant is exercisable at C$0.65 per share (12/22) |
pSivida Ltd. |
Private |
14.23S and 28.46W |
$2.9 |
The shares were sold at A$0.26 each (US$2 ADR equivalent); the four-year warrants are exercisable at A$0.26 per share (12/20) |
ReGen |
Private placement of stock and warrants |
18.8S and 5.64W |
$6.95 |
The stock was sold at $0.37 per share; the five-year warrants are exercisable at $0.55 per share; investors have rights to purchase another 18.8M shares on the same terms if ReGen's collagen scaffold device is approved (12/4) |
RegeneRx Bio- |
Private placement of stock and warrants |
5.306S and 2.122W |
$9.55 |
The stock was sold at $1.80 per share; the warrants are exercisable at $2.75 per share; among the investors was Sigma-Tau Group; Piper Jaffray & Co. was placement agent (12/18) |
SkyePharma |
Loan |
N/A |
£35 ($68.5) |
The loan is repayable over 10 years, based on expected milestone and royalties payments from certain products; the interest is LIBOR plus 5.85% (12/27) |
Xenomics |
Private placement of stock and warrants |
1S and 0.5W |
$1 |
An overseas institutional investor purchased the securities; the six-month warrants are exercisable at $1.25 per share (12/28) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
& = News occurred in November but was not included in previous chart. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; MSE = Madrid Stock Exchange; MYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.